Juno up on Celgene takeout rumors

Juno Therapeutics Inc. (NASDAQ:JUNO) gained $19 (42%) to $64.60 in after-hours trading Tuesday after a report from The Wall Street Journal said Celgene Corp. (NASDAQ:CELG) is in talks to purchase the cell therapy company. As of March 2017, Celgene holds a 9.8% stake in Juno.

Juno declined to comment and Celgene did not respond to inquiries...